Seattle Cancer Care Alliance (SCCA) is recognized as a Center of Excellence by the Myelodysplastic Syndromes Foundation for the diagnosis and treatment of myeloproliferative neoplasms (MPN), also called myeloproliferative disorders, and myelodysplastic syndrome, a group of chronic bone marrow diseases that affect blood-forming stem cells.
The doctors at SCCA and its founding organizations, Fred Hutchinson Cancer Research Center and UW Medicine, are world leaders in research to better understand and more effectively treat these diseases.
SCCA offers a range of standard therapies for MPN such as medications to reduce high blood counts, supportive care to relieve symptoms, and chemotherapy to control abnormal blood cells. Some of our patients benefit from drugs like imatinib (Gleevec) and ruxolitinib (Jakafi), which inhibit abnormal proteins related to specific gene mutations that occur in some types of MPN. In addition, we offer treatments that are not yet commercially available but show promise in clinical studies.
We also offer bone marrow transplantation (also called stem cell transplantation or hematopoietic cell transplantation)—the only treatment option with the potential to cure MPN.